NICE Endorsement Boosts Wegovy's Cardiovascular Market Access in UK

Event summary

  • NICE has recommended Novo Nordisk’s Wegovy (semaglutide 2.4mg) for reducing the risk of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease and overweight or obesity (BMI ≥27 kg/m2).
  • The recommendation is based on the SELECT trial, which showed a 20% reduction in MACE risk (HR 0.80, p<0.001) with semaglutide 2.4mg compared to placebo, independent of weight loss.
  • This marks the first time NICE has recommended a GLP-1 receptor agonist specifically for cardiovascular risk reduction.
  • The recommendation will be incorporated into existing NHS cardiovascular care pathways in England, with Technology Appraisal Guidance expected by the end of April 2026.
  • The absolute risk reduction observed in the SELECT trial was 1.5 percentage points, with MACE occurring in 6.5% of participants receiving semaglutide versus 8.0% receiving placebo.

The big picture

Novo Nordisk’s Wegovy has become a cornerstone of obesity management, and this NICE endorsement significantly expands its therapeutic role into cardiovascular risk reduction, a much larger patient population. This move validates the broader potential of GLP-1 RAs beyond weight loss and positions Novo Nordisk to capitalize on the growing convergence of metabolic and cardiovascular disease treatment. The UK’s NHS adoption will serve as a key case study for other healthcare systems globally considering similar approvals.

What we're watching

Adoption Rate
The speed at which NHS trusts and clinicians integrate Wegovy into existing cardiovascular pathways will determine the initial market penetration and revenue impact for Novo Nordisk.
Competitive Landscape
Other pharmaceutical companies will likely accelerate development of their own GLP-1 therapies targeting cardiovascular outcomes, intensifying competition in this expanding market segment.
Cost Pressures
Continued scrutiny of healthcare spending and NICE’s value assessment may influence future pricing and reimbursement decisions for Wegovy and similar therapies.

Related topics

Pharmaceuticals Regulatory Approval